SUDARSHAN PHARMA IND LTD
Latest filings
Next results: Thu, 29 Oct · Financial Results- Board to review September quarter results and consider fundraising · Results
- Shares to join NSE Capital Market Segment on October 27, 2026 · Capital Market Events
- Sudarshan Pharma scraps plan to acquire 9.50 percent stake in US biotech firm · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells specialty chemicals and pharmaceutical products from GMP-certified facilities at Palghar and Hyderabad. The product range covers pharmaceuticals, active pharmaceutical ingredients (APIs), drugs, chemicals, and healthcare products. Growth has come through acquisitions, including Ratna Lifesciences and a 51% stake in Ishwari Healthcare, and through export expansion, supported by a wholly-owned US subsidiary called Sudarshan Industries Inc. incorporated in Delaware. FY26 revenue was ₹703.0565 crore (up from ₹505 crore in FY25), with net profit of ₹23.3717 crore and an EBITDA margin of 8.5382%. Export turnover for FY25-26 was ₹21.85 crore, with a stated minimum target of ₹100 crore for FY26-27. On the cost side, materials accounted for 5.6% of revenue, employees 1.1%, other operating expenses 3.5%, depreciation 0.5%, and capex 9.8%.
Scorecard
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SUDARSHAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SUDARSHAN PHARMA IND LTD's filed financials and exchange disclosures
What does SUDARSHAN PHARMA IND LTD do?
SUDARSHAN PHARMA IND LTD is a Chemicals & Petrochemicals company listed on NSE and BSE, trading under the symbol SUDARSHAN.
Is SUDARSHAN PHARMA IND LTD profitable?
Yes. Over the trailing twelve months SUDARSHAN PHARMA IND LTD reported a net profit of ₹28 Cr on revenue of ₹871 Cr.
Does SUDARSHAN PHARMA IND LTD pay a dividend?
Not in the latest reported year — SUDARSHAN PHARMA IND LTD's dividend payout for FY26 was nil.
Is SUDARSHAN PHARMA IND LTD debt-free?
No. It reported borrowings of ₹283 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹282 Cr after cash. Debt stands at 1.81× equity. That is higher than 96% of its 99 Specialty Chemicals peers.
Is SUDARSHAN PHARMA IND LTD expensive compared with its peers?
On trailing P/E, SUDARSHAN PHARMA IND LTD ranks 63 of 99 in Specialty Chemicals — cheaper than 37% of them, against an industry median of 22.8×. This is a position, not a valuation judgement.
When are SUDARSHAN PHARMA IND LTD's next results?
Financial Results on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track SUDARSHAN PHARMA IND LTD's announcements?
Every NSE and BSE filing by SUDARSHAN PHARMA IND LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.